Cargando…
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208982/ https://www.ncbi.nlm.nih.gov/pubmed/34135436 http://dx.doi.org/10.1038/s41698-021-00196-x |
_version_ | 1783709033882976256 |
---|---|
author | Thelen, Martin Wennhold, Kerstin Lehmann, Jonas Garcia-Marquez, Maria Klein, Sebastian Kochen, Elena Lohneis, Philipp Lechner, Axel Wagener-Ryczek, Svenja Plum, Patrick Sven Velazquez Camacho, Oscar Pfister, David Dörr, Fabian Heldwein, Matthias Hekmat, Khosro Beutner, Dirk Klussmann, Jens Peter Thangarajah, Fabinshy Ratiu, Dominik Malter, Wolfram Merkelbach-Bruse, Sabine Bruns, Christiane Josephine Quaas, Alexander von Bergwelt-Baildon, Michael Schlößer, Hans A. |
author_facet | Thelen, Martin Wennhold, Kerstin Lehmann, Jonas Garcia-Marquez, Maria Klein, Sebastian Kochen, Elena Lohneis, Philipp Lechner, Axel Wagener-Ryczek, Svenja Plum, Patrick Sven Velazquez Camacho, Oscar Pfister, David Dörr, Fabian Heldwein, Matthias Hekmat, Khosro Beutner, Dirk Klussmann, Jens Peter Thangarajah, Fabinshy Ratiu, Dominik Malter, Wolfram Merkelbach-Bruse, Sabine Bruns, Christiane Josephine Quaas, Alexander von Bergwelt-Baildon, Michael Schlößer, Hans A. |
author_sort | Thelen, Martin |
collection | PubMed |
description | The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition. |
format | Online Article Text |
id | pubmed-8208982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82089822021-07-01 Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy Thelen, Martin Wennhold, Kerstin Lehmann, Jonas Garcia-Marquez, Maria Klein, Sebastian Kochen, Elena Lohneis, Philipp Lechner, Axel Wagener-Ryczek, Svenja Plum, Patrick Sven Velazquez Camacho, Oscar Pfister, David Dörr, Fabian Heldwein, Matthias Hekmat, Khosro Beutner, Dirk Klussmann, Jens Peter Thangarajah, Fabinshy Ratiu, Dominik Malter, Wolfram Merkelbach-Bruse, Sabine Bruns, Christiane Josephine Quaas, Alexander von Bergwelt-Baildon, Michael Schlößer, Hans A. NPJ Precis Oncol Article The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition. Nature Publishing Group UK 2021-06-16 /pmc/articles/PMC8208982/ /pubmed/34135436 http://dx.doi.org/10.1038/s41698-021-00196-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Thelen, Martin Wennhold, Kerstin Lehmann, Jonas Garcia-Marquez, Maria Klein, Sebastian Kochen, Elena Lohneis, Philipp Lechner, Axel Wagener-Ryczek, Svenja Plum, Patrick Sven Velazquez Camacho, Oscar Pfister, David Dörr, Fabian Heldwein, Matthias Hekmat, Khosro Beutner, Dirk Klussmann, Jens Peter Thangarajah, Fabinshy Ratiu, Dominik Malter, Wolfram Merkelbach-Bruse, Sabine Bruns, Christiane Josephine Quaas, Alexander von Bergwelt-Baildon, Michael Schlößer, Hans A. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title | Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title_full | Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title_fullStr | Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title_full_unstemmed | Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title_short | Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
title_sort | cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208982/ https://www.ncbi.nlm.nih.gov/pubmed/34135436 http://dx.doi.org/10.1038/s41698-021-00196-x |
work_keys_str_mv | AT thelenmartin cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT wennholdkerstin cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT lehmannjonas cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT garciamarquezmaria cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT kleinsebastian cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT kochenelena cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT lohneisphilipp cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT lechneraxel cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT wagenerryczeksvenja cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT plumpatricksven cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT velazquezcamachooscar cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT pfisterdavid cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT dorrfabian cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT heldweinmatthias cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT hekmatkhosro cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT beutnerdirk cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT klussmannjenspeter cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT thangarajahfabinshy cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT ratiudominik cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT malterwolfram cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT merkelbachbrusesabine cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT brunschristianejosephine cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT quaasalexander cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT vonbergweltbaildonmichael cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy AT schloßerhansa cancerspecificimmuneevasionandsubstantialheterogeneitywithincancertypesprovideevidenceforpersonalizedimmunotherapy |